newest research on prostate cancer

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts

Prostate cancer articles within Nature Reviews Urology

In Brief | 14 February 2024

ADT intensification to treat biochemically recurrent prostate cancer

• Maria Chiara Masone

Review Article | 02 February 2024

The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men

African American men are disproportionately affected by prostate cancer in the USA. In this Review, the authors discuss the complex interplay of modifiable risk factors that might underlie the glaring prostate cancer disparities observed.

• Jabril R. Johnson
• , Nicole Mavingire
•  &  Rick A. Kittles

Review Article | 02 January 2024

Shared decision-making before prostate cancer screening decisions

In this Review, the authors discuss shared decision-making for prostate cancer screening in terms of definition, prevalence and methods, including decision aids. Facilitators and barriers to shared decision-making are also discussed.

• Kelly R. Pekala
• , Daniela K. Shill
•  &  Sigrid V. Carlsson

Review Article | 19 December 2023

Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer

In this Review, the authors examine the potential synergy between thermal ablation and intratumoural immunotherapy in treating localized prostate cancer. This combination could transform the traditionally cold immunological landscape of prostate cancer into a hot one, enhancing treatment efficacy.

• Denis Séguier
• , Eric S. Adams
•  &  Thomas J. Polascik

Review Article | 14 November 2023

Genetic and biological drivers of prostate cancer disparities in Black men

Genetic and ancestral factors, molecular pathways involving androgen and non-androgen receptor signalling, inflammation, epigenetics, the tumour microenvironment and tumour metabolism are posited as biological factors that potentially contribute to racial disparities in Black men with prostate cancer.

• , Daniel M. Kim
•  &  Stephen J. Freedland

Review Article | 31 October 2023

Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer

Senescent stromal fibroblasts exhibit a senescence-associated secretory phenotype, which can promote prostate cancer development, progression and resistance to therapy. Targeting senescent cells via senotherapeutics might be an attractive preventive or therapeutic option for prostate cancer.

• Joakin O. Mori
• , Isra Elhussin
•  &  Christopher M. Heaphy

Research Highlight | 11 September 2023

Feasibility and potential of an MRI-based prostate cancer screening

Research Highlight | 08 September 2023

A fully transperineal approach for prostate biospy

News & Views | 30 August 2023

PSMA-targeted fluorescence guidance for robotic-assisted prostatectomy

Positive surgical margins are an independent risk factor for biochemical recurrence after radical prostatectomy. However, the identification of residual cancer by eye is highly limited, and frozen sections are not always available or possible for all margins. Prostate-specific membrane antigen-targeted fluorescence guidance might close this gap and enhance the surgeon’s eye.

• Fabian Falkenbach
•  &  Tobias Maurer

Review Article | 21 August 2023

Bioinformatics in urology — molecular characterization of pathophysiology and response to treatment

In this Review, the authors provide an overview of the main bioinformatics tools available for urologists. The main applications of bioinformatics in the field of urological oncology, as well as in benign urological disease, are discussed, with a special focus on molecular characterization of disease physiopathology and response to treatment. Challenges and future perspectives in the field are also discussed.

• Ali Hashemi Gheinani
•  &  Rosalyn M. Adam

Research Highlight | 08 August 2023

New insights into APOBEC-mediated mutagenesis in prostate cancer

In Brief | 08 August 2023

Nicardipine inhibits chemoresistance in prostate cancer

Tuft cells in prostate cancer, platin-l improves cisplatin resistance.

Perspective | 25 July 2023

The potential role of the microbiota in prostate cancer pathogenesis and treatment

The microbiota influences the body in homeostasis and disease, including cancer, and, although specific urinary and gut microbial species have been associated with an increased risk of prostate cancer, causal mechanistic data remain elusive. In this Perspective article, the authors discuss the roles of the microbiota in prostate carcinogenesis and progression, and consider how these might be leveraged for diagnosis and treatment of the disease.

• Nicolò Pernigoni
• , Christina Guo
•  &  Andrea Alimonti

Research Highlight | 10 July 2023

Metabolic alterations drive enzalutamide resistance

Parp inhibitors plus enzalutamide to treat mcrpc.

Review Article | 22 May 2023

Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer

Effects of prostate cancer treatment in sex and gender minority groups, which include gay and bisexual men, transgender women, or transfeminine people, can include altered sexual function in relation to receptive anal and neovaginal intercourse and changes to patients’ role-in-sex, as well as changes in sexual pleasure related to the loss of the prostate as a source of sexual pleasure. In this Review, the authors discuss the prostate as a sexual organ and consider the effects of prostate cancer treatment in patients from these under-represented groups, as well as discussing the need for openness and counselling in patients from sexual and gender minorities.

• Daniel R. Dickstein
• , Collin R. Edwards
•  &  Deborah C. Marshall

Review Article | 17 May 2023

Obesity and prostate cancer — microenvironmental roles of adipose tissue

Current evidence suggests that adipose stromal cells, a component of peri-prostatic white adipose tissue and the tumour microenvironment, have an important role in driving aggressive prostate cancer in obesity. These cells are potential targets of therapies to suppress cancer aggressiveness in obesity.

• Achinto Saha
• , Mikhail G. Kolonin
•  &  John DiGiovanni

Research Highlight | 21 April 2023

PROTACs for prostate cancer

• Louise Stone

Comment | 03 April 2023

Patient preferences in the treatment of genitourinary cancers

Several newly approved therapies have substantially altered the treatment paradigm for multiple genitourinary cancers. Considering the existence of numerous possible treatment approaches, understanding which treatment attributes are most valued by each patient is crucial to physicians to recommend a cancer-directed treatment.

• David J. Benjamin
•  &  Arash Rezazadeh Kalebasty

Consensus Statement | 03 April 2023

Unanswered questions in prostate cancer — findings of an international multi-stakeholder consensus by the PIONEER consortium

In this Consensus Statement, the authors present results from an international multi-stakeholder consensus conducted by the PIONEER consortium to identify the most important questions in the field of prostate cancer that could be addressed using big data.

• Muhammad Imran Omar
• , Steven MacLennan
•  &  Daniel Kotik

Review Article | 24 March 2023

Calcium signalling pathways in prostate cancer initiation and progression

In this Review, the authors provide an overview of the role of calcium as a driver of prostate cancer onset and progression, and discuss the most current therapies targeting the calcium signalling machinery to treat this malignancy.

• Roberto Silvestri
• , Vanessa Nicolì
•  &  Martin D. Bootman

Research Highlight | 16 March 2023

Singling out the immune-suppressive TME in prostate cancer

Rucaparib improves pfs in patients with brca1/2 -altered mcrpc.

Research Highlight | 14 March 2023

The role of GALNT7 as a potential diagnostic marker in prostate cancer

Pi5p4kα: a target in prostate cancer.

Research Highlight | 10 March 2023

Detecting lymph node metastases for personalized radiotherapy in patients with prostate cancer

Review Article | 14 February 2023

Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo

Prostate cancer depends on the hormonal environment for growth. In this Review, the authors describe how this hormonal dependency can be studied in preclinical models. Advantages and limitations of these models are discussed to maximize the transfer of knowledge from scientific research to clinical applications.

• Lucas Germain
• , Camille Lafront
•  &  Étienne Audet-Walsh

Research Highlight | 13 February 2023

GHR expression and prostate cancer proliferation

In Brief | 10 February 2023

PARP inhibitor response in prostate cancer

Metabolic flexibility in ccrcc, immunoproteasome inhibition in crpc.

Research Highlight | 07 February 2023

CMA mediates resistance to androgen inhibitors in prostate cancer

Prostate cancer care for american indians and alaska natives.

Perspective | 17 January 2023

The future of patient-derived xenografts in prostate cancer research

This Perspective covers existing patient-derived xenografts (PDXs) of prostate cancer, and their features and uses in basic and preclinical research. The authors also discuss the need for additional PDXs, and how collaboration in prostate cancer PDX research can be improved.

• Mitchell G. Lawrence
• , Renea A. Taylor
•  &  Gail P. Risbridger

Research Highlight | 11 January 2023

Can systematic biopsy be omitted from the prostate cancer diagnostic pathway?

Research Highlight | 05 January 2023

Modelling AR mutations

In Brief | 04 January 2023

Irreversible electroporation in radio-recurrent prostate cancer

Arbs heterogeneity in prostate cancer progression, cribriform morphology affects mpmri imaging.

Review Article | 04 January 2023

Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations

Mutations in the BRCA1 and BRCA2 tumour suppressor genes are associated with prostate cancer risk, but optimal screening protocols for individuals with these mutations have been a subject of debate. In this Review, the authors discuss the risk associated with BRCA 1/2 mutations and consider how, and whether, a screening programme should be implemented for these individuals.

• Pawel Rajwa
• , Fahad Quhal
•  &  Shahrokh F. Shariat

Research Highlight | 21 December 2022

MRI diagnosis and radical prostatectomy outcomes

Perspective | 12 December 2022

Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?

Combination treatment with androgen deprivation therapy plus chemotherapy or novel hormonal agents showed promising results for the treatment of patients with newly diagnosed metastatic prostate cancer. However, real-world data show a very low uptake of this therapy in clinical practice. In this Perspective, the authors discuss data and potential reasons behind this trend.

• Kenneth Chen
• , Jonathan O’Brien
•  &  Arun A. Azad

In Brief | 08 December 2022

Tumour-suppressing HIIT serum

Research Highlight | 07 December 2022

FOXA2–KIT-driven lineage plasticity in NEPC

Perspective | 23 November 2022

Relationships between holmium laser enucleation of the prostate and prostate cancer

In this Perspective, the authors present clinical scenarios in which prostate hyperplasia and prostate cancer overlap, with a specific focus on holmium laser enucleation of the prostate (HoLEP). Variables associated with incidental prostate cancer detection at HoLEP and prostate cancer development after HoLEP, as well as the role of HoLEP in patients with biopsy-proven prostate cancer, are also discussed.

• Matthew S. Lee
• , Mark A. Assmus
•  &  Amy E. Krambeck

In Brief | 31 October 2022

WGC in patients with localized prostate cancer

Clinical Outlook | 31 October 2022

PSMA-PET to detect prostate cancer recurrence after radiotherapy

PSA dynamics and conventional imaging methods currently used to assess biochemical recurrence of prostate cancer after definitive treatment with radiotherapy are insufficient, especially considering that different salvage options are available. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is a novel imaging method that was shown to be more accurate than conventional imaging in prostate cancer staging, and can have a role in detecting disease recurrence after radiotherapy.

• Omar Alghazo
•  &  Michael O’Callaghan

Clinical Outlook | 24 October 2022

Understanding and managing the cardiovascular risks of androgen deprivation therapy for prostate cancer

Androgen deprivation therapy potentiates cardiovascular morbidity and mortality, which is the most common cause of non-cancer-related death in patients with prostate cancer. Whether the mode of testosterone suppression affects the risk of cardiovascular adverse events is unclear, especially as the 2021 PRONOUNCE trial — which aimed to compare the cardiovascular risks of gonadotropin-releasing hormone (GnRH) antagonists with GnRH agonists — was prematurely terminated.

• Kerem Atalar
•  &  Prabhakar Rajan

Browse broader subjects

• Prostatic diseases
• Urological cancer

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies